Attitudes surrounding cannabis have been steadily softening over the last decade, and now with Canada within a month of full legalization for recreational use, it appears that global acceptance is soon to follow—on not only Main Street, but Wall Street (and Bay Street) as well.
One need not look much further than the newly historic rally witnessed with shares in Tilray Inc. (NASDAQ: TLRY). Just two months after its July IPO, the company is already trading at a premium more than 14 times its IPO price of $17.
New products, and new markets are driving opportunities across the sector for players large and small, including Tilray, Aurora Cannabis (OTC: ACBFF) (TSX: ACB), Canopy Growth Inc. (TSX: WEED) (OTC: TWMJF), Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON), and CROP Infrastructure Corp. (OTC: CRXPF) (CSE: CROP).
Tilray's example of offering a variety of high-quality products to its consumer base is growing trust among doctors, patients in ten countries across five continents. The company is now set to work with the University of California San Diego on a clinical trial to test ... Click here to view full article